The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
What do we really know about the ubiquitin-proteasome pathway in muscle atrophy?
Abstract
Studies of many different rodent models of muscle wasting have indicated that accelerated proteolysis via the ubiquitin-proteasome pathway is the principal cause of muscle atrophy induced by fasting, cancer cachexia, metabolic acidosis, denervation, disuse, diabetes, sepsis, burns, hyperthyroidism and excess glucocorticoids. However, our understanding about how muscle proteins are degraded, and how the ubiquitin-proteasome pathway is activated in muscle under these conditions, is still very limited. The identities of the important ubiquitin-protein ligases in skeletal muscle, and the ways in which they recognize substrates are still largely unknown. Recent in-vitro studies have suggested that one set of ubquitination enzymes, E2(14K) and E3(alpha), which are responsible for the 'N-end rule' system of ubiquitination, plays an important role in muscle, especially in catabolic states. However, their functional significance in degrading different muscle proteins is still unclear. This review focuses on the many gaps in our understanding of the functioning of the ubiquitin-proteasome pathway in muscle atrophy, and highlights the strengths and limitations of the different experimental approaches used in such studies.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“These two systems are controlled by a transcriptional program that upregulates several crucial and rate-limiting enzymes (Glass, 2010; Jagoe and Goldberg, 2001).”
From Proteasome dysfunction induces muscle growth defects and protein aggregation (2014) · cites this paper as Jagoe and Goldberg, 2001
Citations
Cites
The N-end rule: functions, mysteries, uses
Varshavsky, A. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.22.12142 · Cited by 859
Flagged first, then by citations
Research works printed but not linked: 57
- Rock, 1994, Cell, 78, 761, 10.1016/S0092-8674(94)90462-6 · DOI · Paper page
- Schwartz, 1999, Annu Rev Med, 50, 57, 10.1146/annurev.med.50.1.57 · DOI
- Baumeister, 1998, Cell, 92, 367, 10.1016/S0092-8674(00)80929-0 · DOI
- Pickart, 2000, Trends Biochem Sci, 25, 544, 10.1016/S0968-0004(00)01681-9 · DOI
- Lam, 1997, Nature, 385, 737, 10.1038/385737a0 · DOI
- Deshaies, 1999, Annu Rev Cell Dev Biol, 15, 435, 10.1146/annurev.cellbio.15.1.435 · DOI
- Solomon, 1998, J Biol Chem, 273, 25216, 10.1074/jbc.273.39.25216 · DOI
- Bastians, 1999, Mol Biol Cell, 10, 3927, 10.1091/mbc.10.11.3927 · DOI
- Chen, 1995, Genes Dev, 9, 1586, 10.1101/gad.9.13.1586 · DOI
- Lecker, 1999, J Nutr, 129, 227S, 10.1093/jn/129.1.227S · DOI
- Furuno, 1986, Biochem J, 237, 859, 10.1042/bj2370859 · DOI
- Lowell, 1986, Biochem J, 234, 237, 10.1042/bj2340237 · DOI
- Etlinger, 1977, Proc Natl Acad Sci USA, 74, 54, 10.1073/pnas.74.1.54 · DOI
- Hershko, 1992, Annu Rev Biochem, 61, 761, 10.1146/annurev.bi.61.070192.003553 · DOI
- Medina, 1991, Biomed Biochim Acta, 50, 347
- Taillandier, 1996, Biochem J, 316, 65, 10.1042/bj3160065 · DOI
- Mitch, 1994, J Clin Invest, 93, 2127, 10.1172/JCI117208 · DOI
- Wing, 1993, Am J Physiol, 264, E668
- Temparis, 1994, Cancer Res, 54, 5568
- Llovera, 1995, Int J Cancer, 61, 138, 10.1002/ijc.2910610123 · DOI
- Baracos, 1995, Am J Physiol, 268, E996
- Lee, 1998, Trends Cell Biol, 8, 397, 10.1016/S0962-8924(98)01346-4 · DOI · Paper page
- Price, 1996, J Clin Invest, 98, 1703, 10.1172/JCI118968 · DOI
- Bailey, 1996, J Clin Invest, 97, 1447, 10.1172/JCI118566 · DOI
- Tawa, 1997, J Clin Invest, 100, 197, 10.1172/JCI119513 · DOI
- Furuno, 1990, J Biol Chem, 265, 8550, 10.1016/S0021-9258(19)38923-9 · DOI
- Tiao, 1996, J Clin Invest, 97, 339, 10.1172/JCI118421 · DOI
- Medina, 1995, Biochem J, 307, 631, 10.1042/bj3070631 · DOI
- Llovera, 1994, FEBS Lett, 338, 311, 10.1016/0014-5793(94)80290-4 · DOI
- Voisin, 1996, J Clin Invest, 97, 1610, 10.1172/JCI118586 · DOI
- Auclair, 1997, Am J Physiol, 272, C1007, 10.1152/ajpcell.1997.272.3.C1007 · DOI
- Mitch, 1999, Am J Physiol, 276, C1132, 10.1152/ajpcell.1999.276.5.C1132 · DOI
- Wing, 1995, Biochem J, 307, 639, 10.1042/bj3070639 · DOI
- Hobler, 1999, Am J Physiol, 277, R434
- Wing, 1994, Am J Physiol, 267, E39, 10.1152/ajpcell.1994.267.1.C39 · DOI
- Lecker, 1999, J Clin Invest, 104, 1411, 10.1172/JCI7300 · DOI
- Hobler, 1999, Am J Physiol, 276, R468
- Chrysis, 1999, Endocrinology, 140, 5635, 10.1210/en.140.12.5635 · DOI
- Fischer, 2000, Biochem Biophys Res Commun, 267, 504, 10.1006/bbrc.1999.1987 · DOI
- Solomon, 1996, J Biol Chem, 271, 26690, 10.1074/jbc.271.41.25240 · DOI
- Solomon, 1998, Proc Natl Acad Sci USA, 95, 12602, 10.1073/pnas.95.21.12602 · DOI
- Solomon, 2000, J Surg Res, 93, 120, 10.1006/jsre.2000.5958 · DOI
- Bachmair, 1986, Science, 234, 179, 10.1126/science.3018930 · DOI
- Reiss, 1988, J Biol Chem, 263, 2693, 10.1016/S0021-9258(18)69123-9 · DOI
- Baker, 1991, Proc Natl Acad Sci USA, 88, 1090, 10.1073/pnas.88.4.1090 · DOI
- Turner, 2000, Nature, 405, 579, 10.1038/35014629 · DOI
- Bartel, 1990, EMBO J, 9, 3179, 10.1002/j.1460-2075.1990.tb07516.x · DOI
- Kayalar, 1996, Proc Natl Acad Sci USA, 93, 2234, 10.1073/pnas.93.5.2234 · DOI
- Williams, 1999, FASEB J, 13, 1435, 10.1096/fasebj.13.11.1435 · DOI
- Grigoryev, 1996, J Biol Chem, 271, 28521, 10.1074/jbc.271.45.28521 · DOI
- Ciechanover, 1988, J Biol Chem, 263, 11155, 10.1016/S0021-9258(18)37936-5 · DOI
- Gonen, 1996, J Biol Chem, 271, 302, 10.1074/jbc.271.1.302 · DOI
- Roest, 1996, Cell, 86, 799, 10.1016/S0092-8674(00)80154-3 · DOI
- Kwon, 1998, Proc Natl Acad Sci USA, 95, 7898, 10.1073/pnas.95.14.7898 · DOI
- Williams, 1999, Surgery, 126, 744, 10.1016/S0039-6060(99)70131-5 · DOI
- Tiao, 1997, J Clin Invest, 99, 163, 10.1172/JCI119143 · DOI
- Mansoor, 1996, Proc Natl Acad Sci USA, 93, 2714, 10.1073/pnas.93.7.2714 · DOI
Cited by
Sorted by citations
Identification of ubiquitin ligases required for skeletal muscle atrophy.
Bodine, S. C., Latres, E., Baumhueter, S., Lai, V. K.-M., Nunez, L., Clarke, B. A., Poueymirou, W. T., Panaro, F. J., Na, E., Dharmarajan, K., et al. (2001) · Science · doi:10.1126/science.1065874 · Cited by 3,521
Sandri, M., Sandri, C., Gilbert, A., Skurk, C., Calabria, E., Picard, A., Walsh, K., Schiaffino, S., Lecker, S. H., & Goldberg, A. L. (2004) · Cell · doi:10.1016/s0092-8674(04)00400-3 · Cited by 3,012
Self-citationStitt, T. N., Drujan, D., Clarke, B. A., Panaro, F., Timofeyva, Y., Kline, W. O., Gonzalez, M., Yancopoulos, G. D., & Glass, D. J. (2004) · Molecular Cell · doi:10.1016/s1097-2765(04)00211-4 · Cited by 1,964
Atrogin-1, a muscle-specific F-box protein highly expressed during muscle atrophy
Gomes, M. D., Lecker, S. H., Jagoe, R. T., Navon, A., & Goldberg, A. L. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.251541198 · Cited by 1,774
Self-citationBaracos, V. E., Martin, L., Korc, M., Guttridge, D. C., & Fearon, K. C. H. (2018) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2017.105 · Cited by 1,738
Metadata
- Authors
- Jagoe, R. T., & Goldberg, A. L.
- Affiliations
- Harvard University (US)
- Corresponding author
- Goldberg, Alfred L.
- Venue
- Current Opinion in Clinical Nutrition and Metabolic Care
- Published
- 2001-05
- Volume
- 4
- Issue
- 3
- Pages
- 183-190
- ISSN
- 1363-1950 (ISSN-L)
- OpenAlex
- W2024946243
- Cited by
- 399
- References
- 1
- Citations by year
- 2025: 6 · 2024: 5 · 2023: 7 · 2022: 10 · 2021: 9 · 2020: 6 · 2019: 13 · 2018: 9 · 2017: 6 · 2016: 20 · 2015: 16 · 2014: 18 · 2013: 19 · 2012: 26
- FWCI
- 1.43
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Current Opinion in Clinical Nutrition & Metabolic Care (publishedVersion)
- PubMed (publishedVersion)
- Funders
- ALS Association
- Muscular Dystrophy Association
- US-UK Fulbright Commission
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Muscle Physiology and Disorders
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Ubiquitin and proteasome pathways
- Health Sciences › Nursing › Nutrition and Dietetics › Muscle metabolism and nutrition
- Keywords
- ubiquitin-proteasome system, muscle atrophy, skeletal muscle protein degradation, ubiquitin-protein ligase, N-end rule, E2 ubiquitin-conjugating enzyme, E3 ubiquitin ligase, cachexia, denervation, disuse, glucocorticoids, metabolic acidosis, sepsis, burns, hyperthyroidism, diabetes mellitus
- MeSH terms
- Animals, Cysteine Endopeptidases, Humans, Multienzyme Complexes, Muscle Proteins, Muscular Atrophy, RNA, Messenger, Ubiquitins, Cysteine Proteinase Inhibitors, Muscle, Skeletal, Wasting Syndrome, Culture Techniques, Proteasome Endopeptidase Complex
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review